Tumor News and Research

RSS

Deletion on chromosome 11q may guide decision to use chemotherapy for neuroblastoma

When genes are deleted on a particular section of chromosome 11, the result is an aggressive form of the childhood cancer neuroblastoma. A new study suggests that detecting this genetic deletion during the initial evaluation of children with neuroblastoma may indicate to physicians that they should recommend a more aggressive regimen of chemotherapy to fight the cancer.

16 May 2005

Drugs that block the enzyme Odc prevent the onset of cancers

The drug DFMO prevents cancer in laboratory models of lymphoma but fails to kill existing cancerous cells that have lost the ability to self-destruct, according to investigators at St. Jude Children's Research Hospital.

16 May 2005

Identifying high-risk prostate cancer means more prudent treatment decisions

While prostate cancer is a very common diagnosis, it is a deadly disease in relatively few men. One in 6 men will develop prostate cancer during his lifetime. However, of these, only one in 10 cases will be life-threatening.

16 May 2005

New study demonstrates high rates of tumor death in patients receiving regimen

A new pilot study suggests that treating soft-tissue sarcoma with a new regimen of intense chemotherapy and a short course of radiation before surgery may be beneficial. About 41 percent of study participants were found to have complete tumor death at the time of surgery.

16 May 2005

Bevacizumab (Avastin) combined with low-dose chemotherapy slows ovarian cancer

A targeted cancer drug given with low-dose chemotherapy shrank ovarian tumors and slowed progression of ovarian cancer in patients with recurrent disease, according to research findings presented by Agustin Garcia, M.D., principal investigator of the study and Director of Breast Cancer Research at the Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center.

16 May 2005

Tarvacin equivalent plus Docetaxel inhibits breast tumor growth by 93%

Peregrine Pharmaceuticals, Inc., today announced that a research article titled "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice" was published in the May 15 issue of Cancer Research.

16 May 2005

Moderate recreational and work-related physical activity may reduce the risk of ovarian cancer

While the benefits of physical activity in reducing colon and breast cancer are well established, results of studies on exercise and ovarian cancer have been inconclusive. Because ovarian cancer has such a poor prognosis, it is even more important to identify modifiable lifestyle factors that could prevent it.

16 May 2005

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Final results from the largest international study in the treatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere, cisplatin and 5-fluorouracil) had significantly improved overall survival rates compared to patients who received a standard treatment (cisplatin and 5- fluorouracil).

16 May 2005

Zometa reduces bone loss in patients receiving breast cancer treatment

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).

16 May 2005

Unsuspected protein CD147, regulates the production of plaque-forming peptides that are the defining feature of Alzheimer's

Researchers at the Department of Energy's Lawrence Berkeley National Laboratory have discovered an unsuspected subunit of the protein complex gamma-secretase, which plays a central role in Alzheimer's disease.

15 May 2005

Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patients

Patients with a particular type of advanced lung cancer may have a new option based on data presented at the 2005 annual meeting of the American Society of Clinical Oncology showing that combining a drug that cuts off the cancer's blood supply with standard chemotherapy can shrink tumors and extend life.

15 May 2005

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Recent studies of a new anticancer drug show continued response for patients with late-stage kidney cancer. Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), reported a response rate of 40 percent in patients with metastatic (advanced) renal cell (kidney) cancer who received SU11248 in second-line therapy.

15 May 2005

Postmenopausal women who consume even moderate amounts of alcohol may face an increased risk of breast cancer

Postmenopausal women who consume even moderate amounts of alcohol may face an increased risk of breast cancer, particularly if their cancer is fueled by the hormones estrogen or progesterone, according to a data analysis by researchers at Boston's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard School of Public Health.

15 May 2005

Drug trio increases survival rate in head and neck cancers

Adding a third drug to a standard chemotherapy combination can dramatically improve the survival of patients with advanced head and neck cancer, according to research at Dana-Farber Cancer Institute in Boston.

15 May 2005

Counting number of endothelial cells in blood may predict cancer treatment's effectiveness

Counting the amount of a type of normal cell circulating in the blood of people with cancer could predict whether a tumor progresses or responds to therapy, a new study led by the University of Michigan Comprehensive Cancer Center has found. The finding could give doctors an early indication of whether a treatment will be successful, sparing patients months of an ineffective therapy.

15 May 2005

Robotic surgery dramatically reduces physical trauma for head & neck cancer patients

For patients with cancer of the mouth and throat, surgery is a frequent course of treatment, often leading to speech and swallowing dysfunction and external scarring.

15 May 2005

Humans more prone to cancer than chimpanzees

Chimpanzees and humans share a common ancestor, and even today 99 percent of the two species' DNA is identical. But since the paths of man and chimp diverged 5 million years ago, that one percent of genetic difference appears to have changed humans in an unexpected way: It could have made people more prone to cancer.

15 May 2005

Research reveals atomic structure of angiopoietin-2, a key protein involved in the neo-vascularization of solid tumors

A structural biologist from the Virginia Commonwealth University Massey Cancer Center, in collaboration with researchers at Memorial Sloan-Kettering Cancer Center, has identified the crystal structure of a protein that plays a role in supplying nutrients to solid tumors.

11 May 2005

Virus that targets and kills glioblastoma

Yale School of Medicine scientists have identified a virus that targets and kills glioblastoma, a deadly type of human brain tumor resistant to current medical or surgical treatment, according to a study published as the cover article in the Journal of Virology.

11 May 2005

Broken bones may reduce risk of ovarian cancer

The pain and suffering of a broken bone may yield an unexpected benefit – a reduced risk of ovarian cancer.

10 May 2005

Tumor News and Research

Deletion on chromosome 11q may guide decision to use chemotherapy for neuroblastoma

Drugs that block the enzyme Odc prevent the onset of cancers

Identifying high-risk prostate cancer means more prudent treatment decisions

New study demonstrates high rates of tumor death in patients receiving regimen

Bevacizumab (Avastin) combined with low-dose chemotherapy slows ovarian cancer

Tarvacin equivalent plus Docetaxel inhibits breast tumor growth by 93%

Moderate recreational and work-related physical activity may reduce the risk of ovarian cancer

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Zometa reduces bone loss in patients receiving breast cancer treatment

Unsuspected protein CD147, regulates the production of plaque-forming peptides that are the defining feature of Alzheimer's

Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patients

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Postmenopausal women who consume even moderate amounts of alcohol may face an increased risk of breast cancer

Drug trio increases survival rate in head and neck cancers

Counting number of endothelial cells in blood may predict cancer treatment's effectiveness

Robotic surgery dramatically reduces physical trauma for head & neck cancer patients

Humans more prone to cancer than chimpanzees

Research reveals atomic structure of angiopoietin-2, a key protein involved in the neo-vascularization of solid tumors

Virus that targets and kills glioblastoma

Broken bones may reduce risk of ovarian cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News